GigaMune

Cell therapy without the cells.

San Francisco, United States · $2.1M raised

Employees
1–10
Business Model
B2B
Total Funding
$2.1M
Last Round
$400K GrantSep 2025
Rounds
7

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

GigaMune is a San Francisco-based biotechnology company developing in vivo cell therapies for cancer and inherited blood disorders. The company uses powerful bioinformatics algorithms and high-throughput genomics to design viral gene delivery vectors that target T cells directly inside patients, bypassing the costly manufacturing bottleneck of traditional ex vivo CAR-T cell therapy. GigaMune's pipeline targets multiple myeloma, acute myeloid leukemia (AML), and sickle cell disease, and has received multiple SBIR grants from the NIH.

Summary

GigaMune is a Biotech company based in San Francisco, United States. It has raised $2.1M in total across 7 rounds, most recently a $400K Grant round in Sep 2025. Investors include Boost VC, Sand Hill Angels and Reinforced Ventures.

Tech & App Stack

5 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

GrantSBIR Phase I (NIH)Sep 2025
$400K

Sign up to see all 7 events

Funding: Grant. Amounts, valuations, and investors where available.

Investors

Similar Companies

Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020
BridgeBioIPO

BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...

San Francisco Bay Area, United States201–500Biotech, Healthcare
Growth EquityTotal funding$2.7BJul 2026

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

GigaMune on Indexed.vc
<a href="https://indexed.vc/companies/gigamune"><img src="https://indexed.vc/api/badge/company/gigamune" alt="GigaMune on Indexed.vc" width="260" height="76" /></a>